Children and Adults: Average rate of 2 L/minute
Refer to adult dosing.
Refer to adult dosing.
No data reported
No data reported
Concerns related to adverse effects:
• Hypoventilation: Oxygen-induced hypoventilation is the greatest potential hazard of oxygen therapy. In patients with severe COPD, the respiratory drive results from hypoxic stimulation of the carotid chemoreceptors. If this hypoxic drive is diminished by excessive oxygen therapy, hypoventilation may occur and further carbon dioxide retention with possible cessation of ventilation.
• Pulmonary fibrosis: Extended exposure to higher O2 concentrations has been associated with pulmonary fibrosis.
May be product dependent
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Gas, Inhalation:
Generic: 99% (1 ea); 99.5% (1 ea); 99.99% (1 ea)
Treatment of various clinical disorders, both respiratory and nonrespiratory; relief of arterial hypoxia and secondary complications; treatment of pulmonary hypertension, polycythemia secondary to hypoxemia, chronic disease states complicated by anemia, cancer, migraine headaches, coronary artery disease, seizure disorders, sickle-cell crisis, and sleep apnea
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Amiodarone: Oxygen may enhance the adverse/toxic effect of Amiodarone. Specifically, amiodarone pulmonary toxicity may be enhanced. Risk C: Monitor therapy
Bleomycin: Oxygen may enhance the adverse/toxic effect of Bleomycin. Specifically, bleomycin pulmonary toxicity may be enhanced. Management: Attempt to keep oxygen at a concentration equal to that of room air (eg, 25%), during surgery and the post-operative period for patients receiving bleomycin. Monitor patients carefully for pulmonary toxicity, especially those receiving fluid replacement. Risk D: Consider therapy modification
Increased oxygen in tidal volume and oxygenation of tissues at molecular level
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟